Stephen Schey

Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

Jesús F. San Miguel, Katja Weisel, Philippe Moreau et al. · The Lancet Oncology · 2013 · 794 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

In vivo CAMPATH-1H prevents graft-versus-host disease following nonmyeloablative stem cell transplantation

Panagiotis Kottaridis, Donald Milligan, Rajesh Chopra et al. · Blood · 2000 · 502 citations

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Frits van Rhee, Peter M. Voorhees, Angela Dispenzieri et al. · Blood · 2018 · 394 citations · Full text

Phase I Study of an Immunomodulatory Thalidomide Analog, CC-4047, in Relapsed or Refractory Multiple Myeloma

Stephen Schey, Paul Fields, J. Blake Bartlett et al. · Journal of Clinical Oncology · 2004 · 309 citations · Full text

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

Y-T Tai, Yosef Landesman, Chirag Acharya et al. · Leukemia · 2013 · 299 citations · Full text

Tumor Biology, Oncology, Bone Morphogenic Protein +10